The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study
Open accessAbstract
Voretigene neparvovec (VN) is the first available gene therapy for patients with biallelic RPE65-mediated inherited retinal dystrophy who have sufficient viable retinal cells. PERCEIVE is an ongoing, post-authorization, prospective, multicenter, registry-based observational study and is the largest study assessing the real-world, long-term safety and effectiveness of VN. Here, we present the outcomes of 103 patients treated with VN according to local prescribing information. The mean (SD) age was 19.5 (10.85) years, 52 (50.5%) were female, and the mean (SD) duration of the follow up was 0.8 (0.64) years (maximum: 2.3 years). Thirty-five patients (34%) experienced ocular treatment-emergent adverse events (TEAEs), most frequently related to chorioretinal atrophy (n = 13 [12.6%]). Eighteen patients (17.5%; 24 eyes [13.1%]) experienced ocular TEAEs of special interest, including intraocular inflammation and/or infection related to the procedure (n = 7). The mean (SD) changes from baseline in full-field light-sensitivity threshold testing (white light) at month 1, month 6, year 1, and year 2 were −16.59 (13.48) dB (51 eyes), −18.24 (14.62) dB (42 eyes), −15.84 (14.10) dB (10 eyes), and −13.67 (22.62) dB (13 eyes), respectively. The change in visual acuity from baseline was not clinically significant. Overall, the outcomes of the PERCEIVE study are consistent with the findings of VN pivotal clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This prevalence is also seen in post-approval studies of voretigene neparvovec (Kessel et al., 2022; Fischer et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Fischer et al., 2024
The cited source says what the claim attributes to it.
In the citing paper
“Most patients have undergone second eye treatment 7 days after the first eye in real-world use (Fischer et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Fischer et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“In these trials, VN administration to patients with biallelic RPE65 -associated IRD led to improvements in functional vision (multi-luminance mobility test) and visual function (full-field light-sensitivity threshold (FST) and VF) [13–15].”
BackgroundSelf-citationLange, C., Feltgen, N., Junker, B., Schulze-Bonsel, K., & Bach, M. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0926-0 · Cited by 626 · cited 1×
“Off-chart vision measurements were assigned values using the scale adapted from Lange 2009 [21].”
MethodMaguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409
Self-citationDurability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease
Maguire, A. M., Russell, S., Chung, D. C., Yu, Z.-F., Tillman, A., Drack, A. V., Simonelli, F., Leroy, B. P., Reape, K. Z., High, K. A., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.03.031 · Cited by 194 · cited 3×
“In these trials, VN administration to patients with biallelic RPE65 -associated IRD led to improvements in functional vision (multi-luminance mobility test) and visual function (full-field light-sensitivity threshold (FST) and VF) [13–15].”
BackgroundMethodResultSelf-citationRetinal Inflammation, Cell Death and Inherited Retinal Dystrophies
Olivares‐González, L., Velasco, S., Campillo, I., & Rodrigo, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042096 · Cited by 162
Gange, W. S., Sisk, R. A., Besirli, C. G., Lee, T. C., Havunjian, M., Schwartz, H., Borchert, M., Sengillo, J. D., Mendoza‐Santiesteban, C. E., Berrocal, A. M., et al. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.03.016 · Cited by 157
Chiu, W., Lin, T.-Y., Chang, Y.-C., Lai, H. I. A. M., Lin, S.-C., Ma, C., Yarmishyn, A. A., Lin, S.-C., Chang, K.-J., Chou, Y.-B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094534 · Cited by 115
Retinal pigment epithelium 65 kDa protein (RPE65): An update
Kiser, P. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101013 · Cited by 102 · cited 2×
“The RPE65 gene is selectively expressed in retinal pigment epithelium (RPE) cells and encodes the 65-kDa retinoid isomerohydrolase, which converts all-trans -retinyl ester to 11-cis -retinal, an essential step in the regeneration of visual pigment [4,5].”
BackgroundVoretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence
Gao, J., Hussain, R. M., & Weng, C. Y. (2020) · Clinical ophthalmology · doi:10.2147/opth.s231804 · Cited by 86 · cited 1×
“Furthermore, the results show an acceptable safety profile, which is consistent with vitrectomy and the subretinal administration procedure [11,13,14].”
ResultDevelopment of retinal atrophy after subretinal gene therapy with voretigene neparvovec
Reichel, F. F., Seitz, I. P., Wozar, F., Dimopoulos, S., Jung, R., Kempf, M., Kohl, S., Kortüm, F. C., Ott, S., Pohl, L., et al. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-321023 · Cited by 84
Self-citation
Research works printed but not linked: 1
- Isabelle Audo, J.A.S., Barale, P.O., Said, S.M., Devisme, C., Pagot, C., and Chapn, P. (2022, January 21). LIGHT—Observational study on the use of voretigene neparvovec in patients with inherited retinal dystrophy at CHNO des Quinze-Vingts: A 1-year follow-up of a 12-case series. Proceedings of the EURETINA—European Society of Retina Specialists, Hamburg, Germany.
Cited by
Gene therapies for neurogenetic disorders
Devinsky, O., Coller, J., Ahrens‐Nicklas, R. C., Liu, X. S., Ahituv, N., Davidson, B. L., Bishop, K. M., Weiss, Y., & Mingorance, A. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.01.015 · Cited by 33
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
Self-citationMichaelides, M., Laich, Y., Wong, S. C., Oluonye, N., Zaman, S., Kumaran, N., Kalitzeos, A. A., Petrushkin, H., Georgiou, M., Tailor, V., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02812-5 · Cited by 24
“31,32 Subretinal administration of voretigene neparvovec has been reported in children as young as 2 years of age, with measurable improvements in visual acuity in children aged 3–6 years.”
Gene therapy strategies in ophthalmology—an overview of current developments and future prospects
Krajewska, J. B., & Waszczykowska, A. (2025) · Journal of Applied Genetics · doi:10.1007/s13353-025-00973-5 · Cited by 19
“Although the patient population is still very limited, real-world studies provide additional information especially concerning rare adverse events (Sengillo et al. 2022; Deng et al. 2022; Testa et al. 2022; Kiraly et al. 2023; Fischer et al. 2024; Melillo et al. 2024).”
Jia, R., Chen, S., Wang, L., Zhang, J., Qu, B., Qiao, J., Meng, X., Yu, S., Liu, X., Xu, B., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101377 · Cited by 17
“AAV8 is about 10-fold more efficient than AAV2 at transducing RPE and photoreceptor cells with subretinal injection in NHP (Vandenberghe et al., 2011).”
Metadata
- Authors
- Fischer, M. D., Simonelli, F., Sahni, J., Holz, F. G., Maier, R., Fasser, C., Suhner, A., Stiehl, D. P., Chen, B., Audo, I., & Leroy, B. P.
- Affiliations
- University of Oxford (GB)
- University of Campania "Luigi Vanvitelli" (IT)
- Novartis (Switzerland) (CH)
- University of Bonn (DE)
- Retina International, D02 TW98 Dublin, Ireland; Retina Suisse, 8005 Zürich, Switzerland
- Novartis (United States) (US)
- Centre National de la Recherche Scientifique (FR)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Fischer, M. Dominik
- ORCID
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2024-01-17
- Volume
- 14
- Issue
- 1
- Pages
- 122
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC10813228
- OpenAlex
- W4390944289
- Cited by
- 70
- References
- 18
- Citations by year
- 2026: 31 · 2025: 32 · 2024: 7
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Novartis Pharma AG
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- voretigene neparvovec, gene therapy, real-world safety, long-term effectiveness, chorioretinal atrophy, intraocular inflammation, intraocular infection, visual acuity
- MeSH terms
- Adult, Female, Humans, Male, Prospective Studies, Registries, Retina, Genetic Therapy, Choroid Diseases, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study. https://app.cochat.ai/papers/10.3390/biom14010122
- The paper
- Fischer, M. D., Simonelli, F., Sahni, J., Holz, F. G., Maier, R., Fasser, C., Suhner, A., Stiehl, D. P., Chen, B., Audo, I., & Leroy, B. P. (2024). Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study. Biomolecules. https://doi.org/10.3390/biom14010122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.